Overview
Use this article to understand the stepwise Mounjaro® dose escalation schedule, why dose levels cannot be skipped, and how an EU-registered doctor determines clinical suitability for dose increases.
Stepwise Mounjaro® dose escalation schedule
Mounjaro® (tirzepatide) treatment follows a step-by-step titration plan designed to allow your body to adapt gradually to the active ingredient.
Gradual adaptation: Dose increases occur in stepped increments to minimise potential gastrointestinal side effects and help your body build tolerance safely.
Standard dosing progression: Treatment begins at the initial 2.5 mg starting dose for at least 4 weeks. Following clinical review, the dose may increase to 5 mg, then progressively to 7.5 mg, 10 mg, 12.5 mg, and up to the maximum maintenance dose of 15 mg.
Minimum duration per dose: Patients must spend a minimum of 4 weeks on any given dose level before advancing to the next strength.
Dosing rules and clinical suitability
For patient safety and medical compliance, strict rules govern Mounjaro® dose progression:
No skipping dose levels: Prescribing a higher dose than the next step in the established plan is not permitted. For example, moving directly from 2.5 mg to 7.5 mg is not allowed. Skipping dose steps significantly increases the risk of severe side effects.
Clinical assessment required: Increasing your dose is not automatic. Every dose progression requires a medical evaluation by an EU-registered doctor to confirm that your current dose is well tolerated and that increasing the strength is clinically appropriate.
Transfers with proof of prior treatment: If you are transferring care from an alternative provider and request a higher starting dose, you must provide verifiable proof of your previous treatment history and dose level for clinical evaluation.
Additional Assistance
If you still need help after reviewing the information above, additional assistance is available.